Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
etherna develops mRNA and lipid nanoparticle solutions.
EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.
Dopavision is a therapeutic company developing a digital therapeutic for myopia.
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria.
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases.
Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.
T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments.
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Wellth motivates medication adherence using Behavioral Economics
Nuevocor operates as a preclinical-stage biotech company.
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions
Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research.
Asgard Therapeutics is a Biotechnology Company.
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
Acousia Therapeutics is a privately held biotech company.
TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy in a more efficient and practical manner.
C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.
Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity.
Optina Diagnostics develops technology for the early detection of disease through the eye.
Boehringer Ingelheim Venture Fund has invested in 60 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Boehringer Ingelheim Venture Fund's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Medical Device. The firm invests across 20 different industry categories.
Among tracked funding rounds, OncoMyx Therapeutics received $50.0M in a Series B round. Boehringer Ingelheim Venture Fund's total known invested capital is $983.2M.
Boehringer Ingelheim Venture Fund's average investment size is $19.3M across its portfolio of 60 companies.
Recent Boehringer Ingelheim Venture Fund portfolio additions include etherna immunotherapies, EvlaBio, Dopavision, smartbax, ArrePath. These companies were founded in 2020 or later.